bluebird bio Statistics
Total Valuation
bluebird bio has a market cap or net worth of $177.92 million. The enterprise value is $307.33 million.
| Market Cap | 177.92M |
| Enterprise Value | 307.33M |
Important Dates
The next estimated earnings date is Tuesday, August 6, 2024, before market open.
| Earnings Date | Aug 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
bluebird bio has 192.74 million shares outstanding. The number of shares has increased by 33.79% in one year.
| Shares Outstanding | 192.74M |
| Shares Change (YoY) | +33.79% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 0.38% |
| Owned by Institutions (%) | 59.09% |
| Float | 108.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 8.19 |
| Forward PS | 2.00 |
| PB Ratio | 0.80 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.36.
| Current Ratio | 1.55 |
| Quick Ratio | 1.24 |
| Debt / Equity | 1.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 11.94 |
Financial Efficiency
Return on equity (ROE) is -34.30% and return on invested capital (ROIC) is -25.87%.
| Return on Equity (ROE) | -34.30% |
| Return on Assets (ROA) | -14.40% |
| Return on Capital (ROIC) | -25.87% |
| Revenue Per Employee | $67,263 |
| Profits Per Employee | -$282,251 |
| Employee Count | 323 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, bluebird bio has paid $30,000 in taxes.
| Income Tax | 30,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -72.36% in the last 52 weeks. The beta is 0.86, so bluebird bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -72.36% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 1.85 |
| Relative Strength Index (RSI) | 46.57 |
| Average Volume (20 Days) | 6,439,889 |
Short Selling Information
The latest short interest is 29.48 million, so 15.29% of the outstanding shares have been sold short.
| Short Interest | 29.48M |
| Short Previous Month | 29.12M |
| Short % of Shares Out | 15.29% |
| Short % of Float | 27.08% |
| Short Ratio (days to cover) | 6.01 |
Income Statement
In the last 12 months, bluebird bio had revenue of $21.73 million and -$91.17 million in losses. Loss per share was -$0.60.
| Revenue | 21.73M |
| Gross Profit | -2.19M |
| Operating Income | -136.15M |
| Pretax Income | -91.14M |
| Net Income | -91.17M |
| EBITDA | -95.08M |
| EBIT | -99.46M |
| Loss Per Share | -$0.60 |
Balance Sheet
The company has $174.29 million in cash and $303.71 million in debt, giving a net cash position of -$129.41 million or -$0.67 per share.
| Cash & Cash Equivalents | 174.29M |
| Total Debt | 303.71M |
| Net Cash | -129.41M |
| Net Cash Per Share | -$0.67 |
| Equity (Book Value) | 222.54M |
| Book Value Per Share | 1.15 |
| Working Capital | 88.12M |
Cash Flow
In the last 12 months, operating cash flow was -$277.48 million and capital expenditures $191.85 million, giving a free cash flow of -$85.64 million.
| Operating Cash Flow | -277.48M |
| Capital Expenditures | 191.85M |
| Free Cash Flow | -85.64M |
| FCF Per Share | -$0.79 |
Margins
Gross margin is -10.08%, with operating and profit margins of -626.69% and -419.62%.
| Gross Margin | -10.08% |
| Operating Margin | -626.69% |
| Pretax Margin | -419.48% |
| Profit Margin | -419.62% |
| EBITDA Margin | -437.65% |
| EBIT Margin | -457.81% |
| FCF Margin | -394.16% |
Dividends & Yields
bluebird bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -33.79% |
| Shareholder Yield | -33.79% |
| Earnings Yield | -51.24% |
| FCF Yield | -48.13% |
Analyst Forecast
The average price target for bluebird bio is $5.41, which is 486.07% higher than the current price. The consensus rating is "Hold".
| Price Target | $5.41 |
| Price Target Difference | 486.07% |
| Analyst Consensus | Hold |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 126.30% |
| EPS Growth Forecast (5Y) | -52.81% |
Stock Splits
The last stock split was on November 5, 2021. It was a forward split with a ratio of 1544:1000.
| Last Split Date | Nov 5, 2021 |
| Split Type | Forward |
| Split Ratio | 1544:1000 |
Scores
bluebird bio has an Altman Z-Score of -9.43 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.43 |
| Piotroski F-Score | 4 |